Transplacental cisplatin exposure induces persistent fetal mitochondrial and genomic DNA damage in patas monkeys

Reproductive Toxicology

Volumn 11, Issue 1, 1997, Pages 95-100

  Giurgiovich, Alejandra J ^a   Anderson, Lucy M ^b   Jones, Ann B ^b   Dove, Lee F ^b   Moskal, Thomas J ^c   Rice, Jerry M ^b   Olivero, Ofelia A ^a   Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BIOQUAL INC   (United States)

Author keywords

cisplatin DNA dissociation enhanced lanthanide fluoroimmunoassay; DNA adduct; fetal monkey; genomic DNA; mitochondrial DNA

Indexed keywords

CISPLATIN; DNA; MITOCHONDRIAL DNA;

ANIMAL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CERCOPITHECIDAE; DNA ADDUCT; DNA DAMAGE; DRUG EFFECT; FEMALE; FETOMATERNAL TRANSFUSION; FETOTOXICITY; FETUS; FETUS DEVELOPMENT; GENETICS; GENOTOXICITY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MITOCHONDRION; MONKEY; NONHUMAN; PLACENTA; PREGNANCY; PRENATAL DRUG EXPOSURE; PRENATAL EXPOSURE;

ANIMALS; CISPLATIN; DNA ADDUCTS; DNA DAMAGE; DNA, MITOCHONDRIAL; EMBRYONIC AND FETAL DEVELOPMENT; ERYTHROCEBUS PATAS; FEMALE; MATERNAL-FETAL EXCHANGE; ORGAN SPECIFICITY; PLACENTA; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

ANIMALIA; CERCOPITHECIDAE; ERYTHROCEBUS PATAS;

EID: 0030951409     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(96)00201-8     Document Type: Article

References (22)

1. DuBeshter B, Lin J, Angel C, Poulter CA. Gynecologic tumors. In: Rubin P, ed. Clinical oncology: a multidisciplinary approach for physicians and students. Philadelphia: W. B. Saunders; 1993:363.
2. Greene MH. Is cisplatin a human carcinogen? J Natl Cancer Inst. 1992;84:306-12.
3. Christman JE, Teng NN, Lebovic GS, Sikic BI. Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy. Gynecol Oncol. 1990;37:292-5.
4. King LA, Nevin PC, Williams PP, Carson LF. Treatment of advanced epithelial ovarian carcinoma in pregnancy with cisplatin-based chemotherapy. Gynecol Oncol. 1991;41:78-80.
5. Malfetano JH, Goldkrand JW. Cis-platinum combination chemotherapy during pregnancy for advanced epithelial ovarian carcinoma. Obstet Gynecol. 1990;75:545-7.
6. Diwan BA, Anderson LM, Ward JM, Henneman JR, Rice JM. Transplacental carcinogenesis by cisplatin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital. Toxicol Appl Pharmacol. 1995;132:115-21.
7. Diwan BA, Anderson LM, Rehm S, Rice JM. Transplacental carcinogenicity of cisplatin: initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice. Cancer Res. 1993;53:3874-6.
8. Giurgiovich AJ, Diwan BA, Lee KB, Anderson LM, Rice JM, Poirier MC. Cisplatin-DNA adduct formation in maternal and fetal rat tissues after transplacental cisplatin exposure. Carcinogenesis. 1996;17:1665-9.
9. Stewart DJ, Mikhael NZ, Nair RC, et al. Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol. 1988;11: 152-8.
10. Shamkhani H, Anderson LM, Henderson CE, et al. DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod Toxicol. 1994;8:207-16.
11. Henderson CE, Elia G, Garfinkel D, Poirier MC, Shamkhani H, Runowicz CD. Platinum chemotherapy during pregnancy for serous cystadenocarcinoma of the ovary. Gynecol Oncol. 1993;49: 92-4.
12. Rice JM, Rehm S, Donovan PJ, Perantoni AO. Comparative transplacental carcinogenesis by directly acting and metabolism-dependent alkylating agents in rodents and nonhuman primates. IARC Sci Publ. 1989;96:17-34.
13. Olin BR. Drug facts and comparisons. Philadelphia, PA: J. B. Lippincott Co.: 1989.
14. Flamm WG, Birnstiel ML, Walker PMB. Preparation and fractionation and isolation of single strands of DNA by ultracentrifugation in fixed-angle rotors. In: Birnie GD, Fox SM, eds. Subcellular components: preparation and fractionation. London: Butterworths and Company Ltd.: 1967:126-54.
15. Tamura K, Aotsuka T. Rapid isolation method of animal mitochondrial DNA by the alkaline lysis procedure. Biochem Genet. 1988;26:815-9.
16. Olivero OA, Semino C, Kassim A, Lopez-Larraza DM, Poirier MC. Preferential binding of cisplatin to mitochondrial DNA of chinese hamster ovary cells. Mutat Res. 1995;346:221-230.
17. Schoket B, Doty WA, Vincze I, Strickland PT, Assennato G, Poirier MC. Increased sensitivity for determination of polycyclic aromatic hydrocarbon-DNA adducts in human DNA samples by dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA). Cancer Epidemiol Biom Prevent. 1993;2:349-53.
18. Poirier MC, Lippard SJ, Zwelling LA, et al. Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci USA. 1982;79:6443-7.
19. Reed E, Gupta-Burt S, Litterst CL, Poirier MC. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA. Carcinogenesis. 1990;11:2117-21.
20. Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res. 1992; 52:149-53.
21. Giurgiovich AJ, Diwan BA, Olivero OA, Anderson LM, Rice JM, Poirier MC. Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure. Carcinogenesis. 1997; in press.
22. Murata T, Hibasami H, Maekawa S, Tagawa T, Nakashima K, Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. Biochem Int. 1990;20:949-55.